RGD Peptides for Neuroprotection via Integrin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological injuries, such as those caused by mechanical, chemical, thermal, and radiative injuries, as well as surgical operations, are inadequate in addressing the complex series of primary and secondary events leading to neural and glial cell death, including excitotoxicity, inflammation, and apoptosis, which often result in chronic or irreversible encephalopathy and significant disability.
Innovation Solution
Development of concatameric polysignaling proteins composed of monomeric peptide units, specifically RGD derivatives like RGD1, RGD2, RGD3, RGD4, and RGD10-PM, which are used to stimulate regeneration and treatment by crossing the blood-brain barrier, modulating integrin-ECM interactions, and promoting neuroprotection through enhanced resistance to proteolysis and controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurological injuries, then current standard care is provided, but neural cell death and chronic encephalopathy occur due to inadequate addressing of primary and secondary injury events
Solution Approach 1:
The therapy is divided into multiple peptide components (RGD1-RGD4, RGD10-PM) with specific sequences and functions, each targeting different aspects of injury response. The peptides are administered as separate entities that work synergistically to address multiple injury mechanisms simultaneously
Solution Approach 2:
The patent modifies the RGD peptide sequence parameters (length, composition, modification) to optimize their ability to cross the blood-brain barrier, bind to integrins, and resist proteolysis. Different peptide variants are designed with specific properties to target different injury phases and mechanisms
2Reliability
If RGD peptides are used to cross the blood-brain barrier, then neuroprotection is achieved, but the complexity of peptide synthesis and characterization increases
Solution Approach 1:
The RGD peptide sequence serves multiple functions: it acts as a cell penetration signal to cross the blood-brain barrier, serves as a binding motif for integrins to promote cell adhesion and migration, and provides resistance to proteolysis. This multi-functionality reduces the need for separate therapeutic components
Solution Approach 2:
The peptides are synthesized and characterized in advance through established chemical synthesis methods and analytical techniques before clinical use. The sequences are designed to pre-establish their ability to cross the blood-brain barrier and bind to target receptors, ensuring efficacy before administration
3Productivity
If concatameric polysignaling proteins are used to stimulate regeneration, then tissue regrowth is promoted, but the complexity of obtaining and purifying the proteins increases
Solution Approach 1:
The concatameric proteins are constructed from repeated monomeric RGD peptide units arranged in specific sequences (dimer, trimer, tetramer, decamer). This modular segmentation allows for systematic variation of protein length and function while using the same basic building block, simplifying synthesis
Solution Approach 2:
The number of repeated RGD units is varied to create different concatameric forms (RGD2, RGD3, RGD4, RGD10-PM), each with optimized properties for specific regenerative applications. This parameter variation allows tuning of protein stability, binding affinity, and biological activity without requiring entirely different protein designs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These RGD peptides demonstrate neuroprotective and regenerative effects by reducing excitotoxicity, inflammation, and promoting cellular survival and tissue regeneration, as evidenced by their ability to maintain neural viability in multifactorial in vitro models and ex vivo brain slice cultures, offering a promising therapeutic approach for neurological injuries.
Implementation Method 1
modulating integrin-ECM interactions
Implementation Method 2
crossing the blood-brain barrier
Implementation Method 3
enhanced resistance to proteolysis
Data Source
Figure 1~3
Figure 4~6
Figure 7~9
AI summary
The present invention relates to chemical compounds with injury-reducing and/or neuroprotective properties, of the general formula: A1-H2N-(RGD)n-amide-A2 where n=1-10. The compounds are preferably selected from the group: RGD1; RGD2; RGD3; RGD4; AcRGDl; AcRGD3, RGD10-PM; RGD10-PS. A subject of the invention is a method for the preparation of the compound RGD10-PS, and its derivatives, by biological means. Moreover, a subject of the invention involves methodology for the evaluation of the injury-reducing and/or neuroprotective activity of chemical compounds on a cellular level, by in vitro analysis of six injury factors, namely glucose deprivation, sodium azide-induced inhibition of cellular respiration, acidosis induced by sodium lactate acidification at pH 6.35, excitotoxicity induced by NMDA, excitotoxicity induced by glutamic acid and excitotoxicity induced by kainic acid, in neural cells. The present invention also includes also a setup for the evaluation of the neuroprotective activity of the aforementioned chemical compounds.